179 related articles for article (PubMed ID: 8605592)
1. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Mauss S; Adams O; Willers R; Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):469-77. PubMed ID: 8605592
[TBL] [Abstract][Full Text] [Related]
2. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
3. Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
Delta Coordinating Committee
HIV Med; 2001 Jul; 2(3):181-8. PubMed ID: 11737399
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
[TBL] [Abstract][Full Text] [Related]
5. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Schooley RT; Ramirez-Ronda C; Lange JM; Cooper DA; Lavelle J; Lefkowitz L; Moore M; Larder BA; St Clair M; Mulder JW; McKinnis R; Pennington KN; Harrigan PR; Kinghorn I; Steel H; Rooney JF
J Infect Dis; 1996 Jun; 173(6):1354-66. PubMed ID: 8648207
[TBL] [Abstract][Full Text] [Related]
6. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
7. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
8. A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
Gatell JM; Leal M; Mallolas J; Vidal C; Pumarola T; Parra R; Padró S; Caruz A; Falgueras T; Rey C; Sánchez-Quijano A; Torres Y; Lissen E; Jiménez de Anta MT; Soriano E
Antivir Ther; 1996 Apr; 1(2):105-12. PubMed ID: 11321180
[TBL] [Abstract][Full Text] [Related]
9. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Lancet; 1996 Aug; 348(9023):283-91. PubMed ID: 8709686
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
;
AIDS; 1999 Jan; 13(1):57-65. PubMed ID: 10207545
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
[TBL] [Abstract][Full Text] [Related]
12. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; (3):CD002038. PubMed ID: 10908523
[TBL] [Abstract][Full Text] [Related]
13. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Darbyshire J; Foulkes M; Peto R; Duncan W; Babiker A; Collins R; Hughes M; Peto T; Walker A
Cochrane Database Syst Rev; 2000; 2000(2):CD002038. PubMed ID: 10796851
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
[TBL] [Abstract][Full Text] [Related]
15. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1.
Park LP; Graham NM; Jacobson LP; Murphy R; Besley D; Zucconi S; Muñoz A
Clin Infect Dis; 1995 Oct; 21(4):930-7. PubMed ID: 8645842
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups.
Ragni MV; Amato DA; LoFaro ML; DeGruttola V; Van Der Horst C; Eyster ME; Kessler CM; Gjerset GF; Ho M; Parenti DM
Blood; 1995 May; 85(9):2337-46. PubMed ID: 7727768
[TBL] [Abstract][Full Text] [Related]
19. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
[TBL] [Abstract][Full Text] [Related]
20. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
Abrams DI; Goldman AI; Launer C; Korvick JA; Neaton JD; Crane LR; Grodesky M; Wakefield S; Muth K; Kornegay S
N Engl J Med; 1994 Mar; 330(10):657-62. PubMed ID: 7906384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
